Table 1.
Clinical characteristics between the years of 2010 and 2012.
| Variables | Years and total N (%) | ||||
|---|---|---|---|---|---|
| All years (N = 1112) |
2010 (N = 431) |
2011 (N = 430) |
2012 (N = 251) |
P value | |
| Age group | |||||
| 40–49 years | 270 (24%) | 102 (24%) | 118 (27%) | 50 (20%) | 0.25 |
| 50–74 years | 696 (63%) | 271 (63%) | 256 (60%) | 169 (67%) | |
| 75+ years | 146 (13%) | 58 (13%) | 56 (13%) | 32 (13%) | |
| Method of first detection | |||||
| Self-breast exam | 272 (24%) | 118 (28%) | 97 (23%) | 57 (23%) | 0.40 |
| Clinical breast exam | 51 (5%) | 23 (5%) | 15 (3%) | 13 (5%) | |
| Mammogram | 684 (61%) | 251 (58%) | 270 (63%) | 163 (65%) | |
| Ultrasound | 53 (5%) | 22 (5%) | 21 (5%) | 10 (4%) | |
| MRI | 43 (4%) | 14 (3%) | 23 (5%) | 6 (2%) | |
| Other | 9 (1%) | 3 (1%) | 4 (1%) | 2 (1%) | |
| Palpability | |||||
| Nonpalpable | 787 (71%) | 290 (67%) | 318 (74%) | 179 (71%) | 0.10 |
| Palpable | 325 (29%) | 141 (33%) | 112 (26%) | 72 (29%) | |
| Screening frequency | |||||
| Annual | 772 (69%) | 310 (72%) | 295 (69%) | 167 (67%) | 0.30 |
| Biennial | 83 (8%) | 36 (8%) | 36 (8%) | 11 (4%) | |
| Nonregular | 193 (17%) | 69 (16%) | 78 (18%) | 46 (18%) | |
| NA/missing | 64 (6%) | 16 (4%) | 21 (5%) | 27 (11%) | |
| Breast cancer stage | |||||
| Stage 0 | 260 (23%) | 100 (23%) | 109 (25%) | 51 (20%) | 0.66 |
| Stage I | 556 (50%) | 212 (49%) | 211 (49%) | 133 (53%) | |
| Stage II | 235 (21%) | 97 (23%) | 84 (20%) | 54 (22%) | |
| Stage III | 54 (5%) | 19 (4%) | 22 (5%) | 13 (5%) | |
| Stage IV | 1 (0.09%) | 1 (0.23%) | 0 (0%) | 0 (0%) | |
| No residual cancer (after neoadjuvant) | 6 (1%) | 2 (1%) | 4 (1%) | 0 (0%) | |
| Histology | |||||
| DCIS | 253 (23%) | 99 (23%) | 104 (24%) | 50 (20%) | 0.79 |
| DCIS with microinvasion | 21 (2%) | 7 (2%) | 11 (3%) | 3 (1%) | |
| Invasive ductal carcinoma | 663 (59%) | 258 (60%) | 250 (58%) | 155 (62%) | |
| Invasive lobular carcinoma | 108 (10%) | 41 (9%) | 40 (9%) | 27 (11%) | |
| Mixed (tubular, papillary, medullary, etc.) | 67 (6%) | 26 (6%) | 25 (6%) | 16 (6%) | |
| ER status | |||||
| Negative < 10% | 184 (17%) | 59 (14%) | 81 (19%) | 44 (18%) | 0.12 |
| Positive ≥ 10% | 912 (82%) | 365 (85%) | 343 (80%) | 204 (81%) | |
| Unknown/missing | 16 (1%) | 7 (1%) | 6 (1%) | 3 (1%) | |
| PR status | |||||
| Negative < 10% | 334 (30%) | 118 (27%) | 139 (32%) | 77 (31%) | 0.29 |
| Positive ≥ 10% | 762 (69%) | 306 (71%) | 285 (66%) | 171 (68%) | |
| Unknown/missing | 16 (1%) | 7 (2%) | 6 (2%) | 3 (1%) | |
| HER-2 neu status | |||||
| Negative (0, 1+) | 732 (66%) | 279 (65%) | 276 (64%) | 177 (70%) | 0.03 |
| Positive (3+) | 94 (8%) | 36 (8%) | 36 (8%) | 22 (9%) | |
| Equivocal (2+) | 12 (1%) | 10 (2%) | 2 (1%) | 0 (0%) | |
| Unknown/missing | 274 (25%) | 106 (25%) | 116 (27%) | 52 (21%) | |
MRI: magnetic resonance imaging; DCIS: ductal carcinoma in situ; ER: estrogen receptor; PR: progesterone receptor.